Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BioVie Inc.
BioVie Inc. News
Aug 13, 2025 - globenewswire.com
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
Aug 7, 2025 - globenewswire.com
BioVie Inc. Announces Pricing of $12 Million Public Offering
Jul 24, 2025 - globenewswire.com
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
Jul 22, 2025 - globenewswire.com
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
BioVie Inc. Quantitative Score
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
BioVie Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
BioVie Inc. Financials
Table Compare
Compare BIVI metrics with: | |||
|---|---|---|---|
Earnings & Growth | BIVI | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BIVI | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BIVI | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BIVI | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BioVie Inc. Income
BioVie Inc. Balance Sheet
BioVie Inc. Cash Flow
BioVie Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
BioVie Inc. Executives
| Name | Role |
|---|---|
| Mr. Cuong Viet Do M.B.A. | President, Chief Executive Officer & Director |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of R&D and Chief Medical Officer |
| Ms. Joanne Wendy Kim CPA | Chief Financial Officer, Treasurer & Corporate Secretary |
| Mr. Clarence N. Ahlem | Senior Vice President of Operations |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Cuong Viet Do M.B.A. | President, Chief Executive Officer & Director | Male | 1966 | 618K |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of R&D and Chief Medical Officer | 1960 | 560K | |
| Ms. Joanne Wendy Kim CPA | Chief Financial Officer, Treasurer & Corporate Secretary | Female | 1955 | 270K |
| Mr. Clarence N. Ahlem | Senior Vice President of Operations | Male | 1955 | -- |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program | 1966 | -- |
BioVie Inc. Insider Trades
| Date | 7 Aug |
| Name | DO CUONG V |
| Role | President & CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 5000 |
| Date | 7 Aug |
| Name | DO CUONG V |
| Role | President & CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 5000 |
| Date | 20 Nov |
| Name | ROGICH SIGMUND |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 32700 |
| Date | 20 Dec |
| Name | ROGICH SIGMUND |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 22070 |
| Date | 20 Nov |
| Name | BERMAN RICHARD J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 34200 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Aug | DO CUONG V | President & CEO | Acquired | P-Purchase | 5000 |
| 7 Aug | DO CUONG V | President & CEO | Acquired | P-Purchase | 5000 |
| 20 Nov | ROGICH SIGMUND | Director | Acquired | A-Award | 32700 |
| 20 Dec | ROGICH SIGMUND | Director | Acquired | A-Award | 22070 |
| 20 Nov | BERMAN RICHARD J | Director | Acquired | A-Award | 34200 |